Showing 3 posts of 3 posts found.


NHS England increases access to cladribine tablets for multiple sclerosis patients during pandemic

March 3, 2021
Research and Development Cladribine, Mavenclad, Merck, multiple sclerosis

NHS England has updated the Blueteq requirements for patients with highly active relapsing MS starting Merck’s cladribine (Mavenclad) tablets during …


NHS England seals access deals with big pharma for breast cancer and MS

November 9, 2017
Sales and Marketing Cancer, Mavenclad, Merck, NHS, NHS England, NICE, Perjeta, Roche, Simon Stevens, breast cancer, multiple sclerosis

NHS England has entered into a commercial agreement with Merck which aims to provide access to innovative treatments for both …


Seven years later, EC gives approval for Merck KGaA’s MS drug

August 25, 2017
Medical Communications, Sales and Marketing Mavenclad, Merck KGaA, biotech, drugs, multiple sclerosis, pharma, pharmaceutical

In 2011, Merck KGaA had all but given up on its MS drug after having been knocked back by both …

Latest content